Munich Cluster for Systems Neurology
print


Breadcrumb Navigation


Content

iRHOM2 takes control of rheumatoid arthritis

J Clin Invest. 25:1-3 (2013)

Authors/Editors: Lichtenthaler SF.
Publication Date: 2013

LICHTENTHALER-j-clin-invest-2013

Abstract

The cytokine TNF-α is a major drug target for rheumatoid arthritis, an inflammatory joint disorder. An alternative approach is to target the protease TNF-α convertase (TACE), which releases TNF-α from cells. However, because TACE cleaves other proteins involved in development and cancer, a tissue-specific inhibition of TACE in immune cells appears mandatory. In this issue of the JCI, Issuree et al. report that iRHOM2 is a TACE activator in immune cells. Loss of iRHOM2 largely protects mice from inflammatory arthritis, making iRHOM2 a potential drug target for this condition.

Related Links